MET and hepatocellular carcinoma: Loss-of-function AXIN1 mutations and c-Met activation were detected in approximately 4% of human HCC, and coexpression of c-Met together with CRISPR/Cas9–based targeting of Axin1 (sgAxin1) in the mouse liver triggers HCC formation (59).